Placebo to canakinumab
Sponsors
Novartis Pharmaceuticals, Novartis
Conditions
Acute GoutImpaired Glucose ToleranceKnee OsteoarthritisOsteoarthritisType 2 Diabetes Mellitus
Phase 2
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
CompletedNCT01068860
Start: 2010-02-28End: 2010-08-31Updated: 2011-09-05
To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee
CompletedNCT01160822
Start: 2010-04-30End: 2011-07-31Updated: 2012-10-30
A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)
TerminatedNCT04814368
Start: 2021-08-27End: 2024-06-24Updated: 2025-10-24
Phase 3
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
CompletedNCT01029652
Start: 2009-12-31End: 2010-10-31Updated: 2014-01-30
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
CompletedNCT01080131
Start: 2010-03-31End: 2011-10-31Updated: 2014-01-30